New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:13 EDTBMRNBioMarin says change ups chance to hit cognition endpoint, says Janney Capital
Janney Capital noted that BioMarin's PEG-PAL study has been changed in terms of entry criteria, which will delay study results. However, the firm said management acknowledged that they think this change increases the chance of the study hitting the cognition endpoint, which Janney believes would strengthen the drug’s label and commercial outlook if it occurs. Janney has a Buy rating on BioMarin.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
06:38 EDTBMRNBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 21, 2015
07:59 EDTBMRNBioMarin gene therapy an overhang for Baxalta, says JPMorgan
Subscribe for More Information
July 20, 2015
14:32 EDTBMRNFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTBMRNSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
08:47 EDTBMRNBioMarin reports Abrazo Phase 2 trial met threshold for tumor reduction
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use